Merck's human papillomavirus vaccine has been approved for men in China, it said on Wednesday, providing the U.S. drugmaker a ...

EQS-AFR: Merck KGaA: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements ...

Fintel reports that on January 8, 2025, Truist Securities downgraded their outlook for Merck (NYSE:MRK) from Buy to Hold.

US drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's medical products administration. The vaccine has been cleared to be used for males ...

Two late-stage studies published Wednesday in The Lancet show that Astra's Imfinzi and Merck's Keytruda delayed the progress ...

MSD acquires WuXi Vaccines' Dundalk facility with a €500 million investment, creating 1,000 new jobs across Ireland and ...

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $101.02 which represents a slight increase of $1.30 or 1.30% from the prior close of $99.72. The stock opened at $100.13 and touched a ...

M-Trust – which is now in beta test release mode – is described by the company as a "cyber-physical trust platform." ...

Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH).

The winners of ‘Best African Women Researchers Awards’ and ‘Best Young African Researcher Awards’ will be enrolled into ...

Merck's Winrevair (sotatercept) gains UK approval for PAH treatment. Key trial results highlight significant exercise ...